The Medical Briefing  Nephrology

Iptacopan in IgA nephropathy, LIBERATE-D, finerenone versus spironolactone, omega-3 in hemodialysis (PISCES)

Retrospective no. 8/12

The essentials in four articles

■ Glomerular disease
477 patients, 24 months: GFR slope −3.10 vs −6.12 mL/min/year with iptacopan; kidney events 21.4% vs 33.5% (HR 0.57). Serious infections 6.7% vs 2.1%.

■ AKI and critical care
221 adults on acute dialysis: kidney recovery 64% vs 50% with a conservative strategy (1.8 vs 3.1 sessions per week), with no increase in serious adverse events.

■ CKD and dialysis
Target trial emulation (2,268 adults with diabetic CKD): mortality 3.1% with finerenone vs 9.9% with spironolactone (aHR 0.31), kidney progression 4.1% vs 8.5%, hyperkalemia 17.2% vs 26.4%. Observational study.

■ CKD and dialysis
PISCES, 1,228 hemodialysis patients, 4 g/day of omega-3 vs placebo, 3.5-year follow-up: severe cardiovascular events HR 0.57 (95% CI 0.47–0.70), with no excess bleeding.